Lykke Pedersen
Lykke Pedersen
Roche Innovation Center Copenhagen
Verified email at roche.com
Title
Cited by
Cited by
Year
Cell motility as random motion: A review
D Selmeczi, L Li, LII Pedersen, SF Nrrelykke, PH Hagedorn, S Mosler, ...
The European Physical Journal-Special Topics 157 (1), 1-15, 2008
1062008
Modeling oscillatory control in NF-κB, p53 and Wnt signaling
B Mengel, A Hunziker, L Pedersen, A Trusina, MH Jensen, S Krishna
Current opinion in genetics & development 20 (6), 656-664, 2010
692010
Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes
CH Bang-Berthelsen, L Pedersen, T Fløyel, PH Hagedorn, T Gylvin, ...
BMC genomics 12 (1), 97, 2011
472011
Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy
AJ Overgaard, HG Hansen, M Lajer, L Pedersen, L Tarnow, P Rossing, ...
Proteome science 8 (1), 4, 2010
472010
A Wnt oscillator model for somitogenesis
PB Jensen, L Pedersen, S Krishna, MH Jensen
Biophysical journal 98 (6), 943-950, 2010
462010
A kinetic model explains why shorter and less affine enzyme-recruiting oligonucleotides can be more potent
L Pedersen, PH Hagedorn, MW Lindholm, M Lindow
Molecular Therapy-Nucleic Acids 3, e149, 2014
452014
miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer
Y Pan, G Robertson, L Pedersen, E Lim, A Hernandez-Herrera, AC Rowat, ...
Oncotarget 7 (18), 25930, 2016
412016
Expression and localization of microRNAs in perinatal rat pancreas: role of miR-21 in regulation of cholesterol metabolism
L Larsen, MW Rosenstierne, LW Gaarn, A Bagge, L Pedersen, ...
PloS one 6 (10), e25997, 2011
312011
PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization
H Mueller, A Lopez, P Tropberger, S Wildum, J Schmaler, L Pedersen, ...
Hepatology 69 (4), 1398-1411, 2019
212019
Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in vivo
H Javanbakht, H Mueller, J Walther, X Zhou, A Lopez, T Pattupara, ...
Molecular Therapy-Nucleic Acids 11, 441-454, 2018
202018
Dickkopf1-a new player in modelling the wnt pathway
L Pedersen, MH Jensen, S Krishna
PLoS One 6 (10), e25550, 2011
172011
Finding diabetic nephropathy biomarkers in the plasma peptidome by high‐throughput magnetic bead processing and MALDI‐TOF‐MS analysis
HG Hansen, J Overgaard, M Lajer, F Hubalek, P Højrup, L Pedersen, ...
PROTEOMICS–Clinical Applications 4 (8‐9), 697-705, 2010
172010
Comment on “Direct Measurement of the Oscillation Frequency in an Optical-Tweezers Trap by Parametric Excitation”
L Pedersen, H Flyvbjerg
Physical Review Letters 98 (18), 189801, 2007
102007
Identifying suitable target regions and analyzing off-target effects of therapeutic oligonucleotides
L Pedersen, PH Hagedorn, T Koch
Oligonucleotide-Based Therapies, 261-282, 2019
32019
Targeting repeated regions unique to a gene is an effective strategy for discovering potent and efficacious antisense oligonucleotides
L Pedersen, P Hagedorn, J Vikeså, ST Karlsen, P Særmark, T Koch, ...
Molecular Therapy-Nucleic Acids 19, 124-131, 2020
22020
Oligonucleotides for inducing paternal UBE3A expression
V Costa, M Hedtjärn, M Hoener, R Jagasia, MA Jensen, C Patsch, ...
US Patent 10,494,633, 2019
22019
COMBINATION TREATMENT OF LIVER-TARGETED HBV LOCKED NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDE AND TLR7 AGONIST RO7020531 LEADS TO PROLONGED OFF-TREATMENT ANTIVIRAL EFFECT IN THE …
J Blaising, Y Yu, X Zhou, L Pedersen, S Wildum, S Ottosen, C Wat, L Gao, ...
Hepatology 70, 428A-429A, 2019
22019
A NOVEL LIVER-DIRECTED LOCKED NUCLEIC ACID TARGETING PD-L1 EXPRESSION REVERTS HBV-SPECIFIC IMMUNE TOLERANCE AND INDUCES SUSTAINED CLEARANCE OF HBV INFECTION
J Zhao, L Pedersen, J Blaising, M Ait-Goughoulte, F Shen, Y Yu, J Walther, ...
HEPATOLOGY 70, 431A-431A, 2019
22019
Oligonucleotides for inducing paternal UBE3A expression
V Costa, M Hedtjärn, M Hoener, R Jagasia, MA Jensen, C Patsch, ...
US Patent 10,739,332, 2020
12020
Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
H Javanbakht, S Ottosen, L Pedersen, H Mueller
US Patent App. 16/310,789, 2019
12019
The system can't perform the operation now. Try again later.
Articles 1–20